RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy Kresladi for severe leukocyte adhesion deficiency‑I (an ultra‑rare disease). Despite the approval, Rocket Pharmaceuticals' shares fell, suggesting investor disappointment or profit‑taking; the approval is strategically important but addresses a very small patient population, limiting immediate revenue upside. Investors appear focused on near‑term commercial potential and positioning rather than the regulatory milestone alone.

Analysis

The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy Kresladi for severe leukocyte adhesion deficiency‑I (an ultra‑rare disease). Despite the approval, Rocket Pharmaceuticals' shares fell, suggesting investor disappointment or profit‑taking; the approval is strategically important but addresses a very small patient population, limiting immediate revenue upside. Investors appear focused on near‑term commercial potential and positioning rather than the regulatory milestone alone.